{"symbol":"JNJ","fiscalQuarter":"Q2-2026","reportDate":"2026-07-15","reportTime":"BMO","status":"upcoming","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q2-2026","estimates":{"consensusEps":2.8388,"consensusRevenue":24999.68,"epsLow":2.65,"epsHigh":3,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Johnson & Johnson (JNJ) is a leading health care company known for its pharmaceuticals, medical devices, and consumer health products. With a market cap of $632 billion, it plays a significant role in the health care sector, impacting everything from medications to personal care items.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"$2.84"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and market demand for its products.","consensus":"$25.0B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Johnson & Johnson to report solid earnings this quarter, with a consensus EPS of $2.84 and revenue of $25.0 billion. The company's strong history of beating EPS estimates adds to the optimistic outlook.","bullCase":"If Johnson & Johnson exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.","bearCase":"Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects and market competition, resulting in a negative stock reaction."},"optionsSignal":{"impliedMove":"7.37%","context":"The options market is pricing in a significant potential move in either direction, indicating uncertainty around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+1.09%","reaction":"+0.90%"},{"quarter":"Q4-2025","epsSurprise":"+1.07%","reaction":"-0.09%"},{"quarter":"Q3-2025","epsSurprise":"+0.94%","reaction":"-0.03%"},{"quarter":"Q2-2025","epsSurprise":"+4.53%","reaction":"+6.19%"},{"quarter":"Q1-2025","epsSurprise":"+7.91%","reaction":"-0.48%"}],"pivotalQuestions":[{"question":"Will Johnson & Johnson's EPS exceed the consensus estimate of $2.84?","whyItMatters":"A beat on EPS would reinforce investor confidence in the company's growth and operational efficiency."},{"question":"What insights will management provide regarding revenue growth and product demand?","whyItMatters":"Understanding revenue drivers is crucial for assessing the company's market position and future growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $2.90 or higher would confirm strong operational performance and investor confidence.","bearTrigger":"An EPS below $2.70 would raise concerns about demand and profitability.","context":"This quarter's performance is critical as it will reflect the company's ability to navigate market challenges and maintain growth."},"scenarioPlaybook":{"beatAndRaise":"If Johnson & Johnson beats expectations, history suggests a positive stock reaction of around +1.22%, confirming strong demand and operational efficiency.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.","miss":"A miss could lead to a decline, with historical patterns indicating a potential drop of around -0.48%."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the impact of recent product launches, which could drive higher-than-expected revenue growth this quarter.","supportingPoints":["Johnson & Johnson has consistently beaten EPS estimates in recent quarters, suggesting strong operational execution.","The options market is pricing a larger move than historical averages, indicating potential for a significant reaction."],"riskToConsensus":"If revenue growth comes in below $24.6 billion, it could challenge the bullish consensus."},"whatToListenFor":["Any commentary on the performance of new pharmaceutical products.","Updates on cost management strategies and their impact on margins.","Insights into market demand trends for consumer health products.","Management's outlook on future revenue growth and market conditions.","Any potential changes in guidance or strategic direction."],"metaDescription":"Johnson & Johnson (JNJ) reports Q2 2026 earnings July 15. Analysts expect $2.84 EPS on $25.0B revenue. Here's what to watch."}}